Abstract

BackgroundEfficiency of colorectal carcinoma treatment by chemotherapy is diminished as the resistance develops over time in patients. The same holds true for 5-fluorouracil, the drug used in first line chemotherapy of colorectal carcinoma.MethodsChemoresistant derivative of HT-29 cells was prepared by long-term culturing in increasing concentration of 5-fluorouracil. Cells were characterized by viability assays, flow cytometry, gene expression arrays and kinetic imaging. Immunomagnetic separation was used for isolation of subpopulations positive for cancer stem cells-related surface markers. Aldehyde dehydrogenase expression was attenuated by siRNA. In vivo studies were performed on SCID/bg mice.ResultsThe prepared chemoresistant cell line labeled as HT-29/EGFP/FUR is assigned with different morphology, decreased proliferation rate and 135-fold increased IC50 value for 5-fluorouracil in comparison to parental counterparts HT-29/EGFP. The capability of chemoresistant cells to form tumor xenografts, when injected subcutaneously into SCID/bg mice, was strongly compromised, however, they formed distant metastases in mouse lungs spontaneously. Derived cells preserved their resistance in vitro and in vivo even without the 5-fluorouracil selection pressure. More importantly, they were resistant to cisplatin, oxaliplatin and cyclophosphamide exhibiting high cross-resistance along with alterations in expression of cancer-stem cell markers such as CD133, CD166, CD24, CD26, CXCR4, CD271 and CD274. We also detected increased aldehyde dehydrogenase (ALDH) activity associated with overexpression of specific ALDH isoform 1A3. Its inhibition by siRNA approach partially sensitized cells to various agents, thus linking for the first time the ALDH1A3 and chemoresistance in colorectal cancer.ConclusionOur study demonstrated that acquired chemoresistance goes along with metastatic and migratory phenotype and can be accompanied with increased activity of aldehyde dehydrogenase. We describe here the valuable model to study molecular link between resistance to chemotherapy and metastatic dissemination.

Highlights

  • Efficiency of colorectal carcinoma treatment by chemotherapy is diminished as the resistance develops over time in patients

  • Acquired resistance is associated with multiple alterations in HT-29/enhanced green fluorescent protein (EGFP)/FUR cells We derived chemoresistant cell line variant HT-29/ EGFP/FUR by continuous culture of HT-29/EGFP cells in increasing concentration of 5-FU, and selection of surviving cells for 8 months

  • In order to compare the response of HT-29/EGFP and its chemoresistant counterparts to 5-FU, we used the luminescent assay based on adenosine triphosphate (ATP) quantitation representative of metabolically active cells

Read more

Summary

Introduction

Efficiency of colorectal carcinoma treatment by chemotherapy is diminished as the resistance develops over time in patients. The same holds true for 5-fluorouracil, the drug used in first line chemotherapy of colorectal carcinoma. Even though there has been a decline in incidence in the past two decades due to better cancer screening measures, the morbidity has not decreased as substantially as those with other types of cancer. This could be changed with expanding knowledge of the biology of colon cancer cells, with the subset of chemoresistant cells [1]. The resistance was proposed to be promoted through soluble factors with progranulin identified as a potential mediator of chemoresistance [3], through activation of TGF-β pathway [4] or the mechanism of CXCR4/PI3K/ Akt downnstream signaling [5]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call